Johnson & Johnson recently published the transcript of their second-quarter 2025 earnings conference call, held on July 16, 2025. The event was attended by key figures from the company, including Chairman and CEO Joaquin Duato, Chief Financial Officer Joseph Wolk, and various Executive Vice Presidents from different divisions. During the call, management highlighted the strength of their diversified business and projected elevated growth in the second half of the year. They discussed anticipated approvals and submissions in critical areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular treatments. These developments are expected to "extend and improve lives in transformative ways and deliver significant value to patients and shareholders." The call was led by Darren Snellgrove, Vice President of Investor Relations, who emphasized the company's optimistic outlook and strategic advancements. The company encouraged listeners to stay informed about their progress and future announcements. The full transcript can be accessed through the link below.